Our research group, in partnership with another compound synthesis laboratory, is interested in finding new molecules that modulate the canonical Wnt pathway. When it is exacerbated this pathway can trigger diseases such as colon and rectal cancer. However when this pathway is in low activity, it could result in degenerative diseases such as osteodegeneration, Alzheimer's and Parkinson's. Studying the effects of these modulations becomes an alternative for proposing therapeutic strategies to be applied in these diseases. In our laboratory we use cell line culture as a tool to select molecules with an activating or inhibitory profile in the Wnt β-catenin pathway, and to better understand this modulation process. To evaluate the modulation profile of these compounds, we used two cell lines with a reporter of the canonical Wnt pathway, the colorectal cancer line RKO and the neural line Neuro-2a, which allows us to evaluate through a luminescence assay how much Treatment of the tested compounds activates or inhibits the Wnt β-catenin pathway. After this selection of compounds, we used other neural or colorectal cancer cell lines, which allow us to better understand the mechanisms of the modulation process of the canonical Wnt pathway.